William Donnellan, MD, was recently promoted to director of Leukemia/Myelodysplastic Syndrome Research at Sarah Cannon. Donnellan original joined Sarah Cannon in 2014 as an investigator of hematologic malignancies. After graduating from Auburn, he earned his medical degree at the University of Alabama School of Medicine. He then completed residency and a fellowship in hematology/oncology with a special focus on blood and marrow transplantation at UAB in nearby Birmingham. In addition to his role at Sarah Cannon, Donnellan is an associate with Tennessee Oncology, PLLC.
In other news, three new research faculty members have been appointed to the drug development programs in Nashville and Denver. Saurin Chokshi, MD, from Yale University, and Meredith McKean, MD, from MD Anderson Cancer Center, will be joining Sarah Cannon Research Institute at Tennessee Oncology in Nashville this summer. Shiraj Sen, MD, from MD Anderson Cancer Center, will be a part of Sarah Cannon Research Institute at HealthONE in Denver. Locally, Chokshi will be focusing on GI cancers and early phase clinical trials under the leadership of Axel Grothey, MD, who was recently announced as the director of Sarah Cannon's GI Cancer Research. McKean will focus her efforts on melanoma, and she will be taking on that cancer program while leading investigational therapy trials.